[WIP] Longevity Science

Introduction

Longevity science studies the biological processes of aging and seeks interventions to extend both lifespan (total years lived) and healthspan (years lived in good health). The field has advanced dramatically with the identification of conserved aging mechanisms across species and the development of measurable [[Biomarkers of Aging|biomarkers]].

Related: [[Biological Age Assessment]] | [[Longevity Interventions]]

The Hallmarks of Aging

The hallmarks of aging framework, first introduced in 2013 and updated in 2023, consolidates scientific insights into the fundamental mechanisms of aging. These hallmarks represent potential intervention points for longevity therapies.

Primary Hallmarks

1. Genomic Instability

[!note] DNA Damage Accumulation Continuous exposure to endogenous and exogenous DNA damaging agents leads to accumulation of genetic alterations throughout life.

Key Mechanisms:

  • DNA damage from oxidative stress, replication errors, and environmental factors

  • Reduced DNA repair capacity with age

  • Accumulation of somatic mutations

  • Nuclear architecture deterioration

Interventions:

  • DNA repair pathway enhancement

  • Antioxidant therapies

  • Caloric restriction

2. Telomere Attrition

Overview: Telomeres are protective DNA caps on chromosomes that shorten with each cell division.

Aging Impact:

  • Telomere shortening triggers cellular senescence

  • Critically short telomeres activate DNA damage response

  • Progressive loss of regenerative capacity

Important Findings (2025):

  • Inflammaging drives telomere attrition (β = 0.98, p = 0.035)

  • Epigenetic clocks like [[Biomarkers of Aging#GrimAge|GrimAge]] outperform telomere length in mortality prediction

  • Association between telomere length and grip strength is mediated by inflammatory burden

Interventions:

  • Telomerase activation (experimental, cancer risk concerns)

  • Lifestyle modifications (exercise, stress reduction)

  • Anti-inflammatory interventions

3. Epigenetic Alterations

[!tip] Epigenetic Reprogramming The epigenome changes with age through DNA methylation, histone modifications, and chromatin remodeling. These changes are reversible, making them prime therapeutic targets.

Key Changes:

  • Global DNA hypomethylation

  • Regional hypermethylation (especially at CpG islands)

  • Loss of heterochromatin

  • Altered histone modification patterns

Breakthrough Research:

  • Horvath Clock: r = 0.97 correlation with chronological age

  • DNAm PhenoAge: Superior predictor of mortality and healthspan

  • [[Longevity Interventions#Yamanaka Factors|Yamanaka factors]] can reverse epigenetic age

2025 Advances:

  • SB000: First single-gene intervention rivaling Yamanaka factors without pluripotency risks

  • Partial reprogramming extends median remaining lifespan by 109% in aged mice

  • Epigenetic age reversal demonstrated in multiple cell types

4. Loss of Proteostasis

Definition: Progressive decline in protein quality control mechanisms.

Components:

  • Heat shock proteins (HSPs) decline with age

  • Unfolded protein response (UPR) becomes impaired

  • Autophagy and proteasome function decrease

  • Accumulation of misfolded/aggregated proteins

Recent Findings (2025):

  • HSP levels decline with age, reducing capacity to handle protein misfolding

  • Small heat shock proteins (sHsps) prevent protein aggregation via ATP-independent chaperone activity

  • Large HSPs (60, 70, 90) interact directly with amyloid beta oligomers

  • Ribosomal proteins and mitochondrial chaperones decrease in aged animals

Diseases Linked to Proteostasis Loss:

  • Alzheimer's disease (amyloid beta, tau aggregation)

  • Parkinson's disease (alpha-synuclein aggregation)

  • Type 2 diabetes (islet amyloid)

5. Mitochondrial Dysfunction

[!warning] Energy Production Decline Mitochondria are the cell's powerhouses. Their dysfunction is central to aging and age-related diseases.

Manifestations:

  • Decreased ATP production

  • Increased reactive oxygen species (ROS)

  • Mitochondrial DNA mutations

  • Impaired mitophagy (selective autophagy of damaged mitochondria)

  • Altered mitochondrial dynamics (fusion/fission imbalance)

Impact on Aging:

  • Reduced cellular energy availability

  • Oxidative damage to proteins, lipids, DNA

  • Activation of inflammatory pathways

  • Metabolic dysregulation

Key Intervention: [[Longevity Interventions#Urolithin A|Urolithin A]]

  • 2025 clinical trial: 1,000 mg daily for 4 weeks

  • Expanded naive-like CD8+ cells (+0.50 percentage points)

  • Increased CD8+ fatty acid oxidation (+14.72 percentage points)

  • Enhanced mitochondrial biogenesis

  • Upregulated T-cell stemness genes (TCF7, LEF1, IL7R)

6. Cellular Senescence

Definition: Irreversible cell cycle arrest accompanied by a pro-inflammatory secretory phenotype (SASP).

Senescence-Associated Secretory Phenotype (SASP):

  • Pro-inflammatory cytokines (IL-6, IL-8, TNF-α)

  • Matrix metalloproteinases

  • Growth factors

  • Chemokines

Beneficial vs. Harmful:

  • Beneficial: Wound healing, tumor suppression, embryonic development

  • Harmful: Chronic accumulation drives inflammation, tissue dysfunction

Therapeutic Approach: [[Longevity Interventions#Senolytics|Senolytics]]

7. Stem Cell Exhaustion

Overview: Progressive loss of stem cell regenerative capacity with age.

Mechanisms (2025 Research):

Intrinsic Factors:

  • Telomere shortening (Hayflick limit)

  • DNA damage accumulation

  • Epigenetic modifications

  • Mitochondrial dysfunction

Extrinsic Factors:

  • Niche deterioration

  • Oxidative stress

  • Chronic inflammation

  • Senescent cell accumulation

2025 Breakthrough: Mount Sinai researchers reversed aging in blood-forming stem cells by correcting lysosomal defects:

  • Lysosomal hyperactivation drives stem cell aging

  • Ex vivo lysosomal inhibitor treatment boosted blood-forming capacity >8-fold

  • Demonstrates reversibility of stem cell aging

Five Hallmarks of Stem Cell Aging (2025):

  1. Loss of division capacity

  2. Impaired differentiation

  3. Altered niche interaction

  4. Metabolic reprogramming

  5. Inflammatory activation

Secondary Hallmarks

8. Altered Intercellular Communication

Changes:

  • Chronic inflammation ("inflammaging")

  • Immunosenescence (immune system aging)

  • Endocrine signaling alterations

  • Neurohormonal dysregulation

Inflammaging Markers:

  • Elevated IL-6, TNF-α, CRP

  • Increased NF-κB activation

  • Reduced anti-inflammatory capacity

Impact:

  • Tissue dysfunction

  • Increased disease susceptibility

  • Reduced stress resistance

9. Dysregulated Nutrient Sensing

[!note] Key Longevity Pathways Nutrient-sensing pathways are evolutionarily conserved regulators of lifespan across species.

Major Pathways:

a) Insulin/IGF-1 Signaling (IIS)

  • Reduced IIS extends lifespan in worms, flies, mice

  • Trade-off: reproduction vs. longevity

  • Influenced by caloric restriction

b) mTOR (Mechanistic Target of Rapamycin)

  • Central regulator of cell growth and metabolism

  • Hyperactivation promotes aging

  • Inhibition (e.g., by rapamycin) extends lifespan

  • Integrates nutrient, energy, and growth signals

c) AMPK (AMP-Activated Protein Kinase)

  • Energy sensor activated by low ATP/high AMP

  • Promotes catabolic processes (autophagy, fatty acid oxidation)

  • Activated by metformin and exercise

  • Works synergistically with sirtuins

d) Sirtuins (NAD+-Dependent Deacylases)

  • SIRT1-7 regulate metabolism, stress resistance, genome stability

  • SIRT1 negatively regulates mTOR via TSC2 interaction

  • SIRT3 activates LKB1/AMPK axis, modulating autophagy

  • Activity declines with age due to NAD+ depletion

Pathway Interactions:

  • SIRT1 inhibits mTOR signaling

  • SIRT3 activates AMPK → inhibits mTOR

  • AMPK and sirtuins converge on autophagy activation

  • All pathways influenced by caloric restriction

Therapeutic Implications: See [[Longevity Interventions#Pathway Modulators|Pathway Modulators]] for interventions targeting these systems.

Convergence on Key Mechanisms

Autophagy: The Cellular Recycling System

[!tip] Central to Longevity Multiple hallmarks and interventions converge on autophagy as a master regulator of cellular health and longevity.

What is Autophagy?

  • Self-eating: degradation and recycling of cellular components

  • Types: macroautophagy, microautophagy, chaperone-mediated autophagy

  • Essential for protein and organelle quality control

Regulation:

  • Activated by: AMPK, sirtuins, caloric restriction, fasting, exercise

  • Inhibited by: mTOR, nutrient abundance, insulin signaling

Role in Aging:

  • Autophagy declines with age

  • Impaired autophagy → accumulation of damaged proteins and organelles

  • Autophagy induction extends lifespan across species

Induction Methods:

  • [[Longevity Interventions#Fasting Mimicking Diet|Fasting and caloric restriction]]

  • Exercise

  • [[Longevity Interventions#Rapamycin|Rapamycin]] (mTOR inhibitor)

  • [[Longevity Interventions#Spermidine|Spermidine]]

  • NAD+ boosters (activate sirtuins)

2025 Research Highlights:

  • Fasting is essential for caloric restriction benefits (Alzheimer's model)

  • 3 cycles of FMD reduced biological age by 2.5 years

  • Autophagy activation improves cardiometabolic health

  • Urolithin A induces mitophagy → improved mitochondrial quality

NAD+ Metabolism and Aging

NAD+ (Nicotinamide Adenine Dinucleotide):

  • Essential coenzyme in energy metabolism

  • Required for sirtuin activity

  • Declines ~50% from age 20 to 60

Consequences of NAD+ Decline:

  • Reduced sirtuin activity

  • Mitochondrial dysfunction

  • Impaired DNA repair

  • Decreased cellular energy

NAD+ Boosting Strategies:

  • NMN (Nicotinamide Mononucleotide)

  • NR (Nicotinamide Riboside)

  • Niacin (Vitamin B3)

  • See [[Longevity Interventions#NAD+ Precursors|NAD+ Interventions]]

Measuring Biological Age

Multiple validated methods exist to assess biological vs. chronological age:

  1. [[Biological Age Assessment#Epigenetic Clocks|Epigenetic Clocks]] - Gold standard

    • Horvath Clock (353 CpG sites, r=0.97)

    • DNAm PhenoAge (513 CpG sites)

    • GrimAge (superior mortality prediction)

  2. [[Biological Age Assessment#Phenotypic Age|PhenoAge]] - Most accessible

    • 9 blood biomarkers + chronological age

    • Strong mortality prediction

  3. [[Biological Age Assessment#Klemera-Doubal Method|Klemera-Doubal Method]] - Most validated

    • Statistical combination of multiple biomarkers

    • Best mortality prediction in systematic reviews

  4. Functional Assessments

    • Grip strength

    • Walking speed

    • Cognitive function

See [[Biological Age Assessment]] for detailed implementation guidance.

Current State of the Field (2025)

Clinical Translation

[!note] From Lab to Clinic Multiple longevity interventions have entered human clinical trials, marking a shift from basic research to translational medicine.

Compounds in Human Trials (2025):

  • At least 10 AI-identified compounds in trials

  • Senolytics (dasatinib + quercetin, fisetin)

  • NAD+ precursors (NMN, NR)

  • Metformin (TAME trial ongoing)

  • Rapamycin (various trials)

  • Urolithin A (immune aging, cardiovascular)

Proven Interventions:

  1. Lifestyle: Exercise, caloric restriction, sleep optimization

  2. Pharmaceuticals: Metformin (diabetes patients show longevity effects)

  3. Supplements: NAD+ precursors show promising human data

Technology Integration

AI and Machine Learning:

  • Drug discovery acceleration

  • Biological age clock development

  • Personalized intervention prediction

  • Multi-omic data integration

Wearables and Digital Health:

  • Continuous biomarker monitoring

  • Real-time intervention feedback

  • Large-scale population studies

Future Directions

Near-Term (1-3 years)

  • Widespread adoption of biological age testing

  • Clinical validation of senolytics

  • Personalized longevity medicine protocols

  • Integration of wearable data with biomarkers

Mid-Term (3-7 years)

  • Epigenetic reprogramming therapies

  • Organ-specific anti-aging interventions

  • Stem cell rejuvenation therapies

  • Advanced combination treatments

Long-Term (7+ years)

  • Comprehensive multi-system rejuvenation

  • Predictive longevity AI

  • Preventive aging medicine as standard care

  • Significant healthspan extension in humans

Implications for Aarogyadost

Integration Opportunities

  1. Biological Age Assessment

    • Implement PhenoAge calculator (blood tests)

    • Track changes over time

    • Validate interventions

    • See [[Biological Age Assessment#Implementation Recommendations]]

  2. Intervention Tracking

    • Monitor lifestyle modifications

    • Supplement tracking and efficacy

    • Exercise and diet optimization

    • Sleep quality metrics

  3. Personalized Recommendations

    • AI-driven intervention suggestions

    • Risk stratification

    • Progression monitoring

    • Outcome prediction

  4. Research Collaboration

    • Indian population aging studies

    • Biomarker validation

    • Intervention efficacy trials

    • Traditional medicine integration

Key Research Organizations

Leading Institutions

  • Buck Institute for Research on Aging

  • Salk Institute (epigenetic reprogramming)

  • Harvard Medical School (Sinclair lab)

  • Mayo Clinic (senolytics research)

  • USC Longevity Institute (Valter Longo)

  • Mount Sinai (stem cell aging)

Industry Leaders

  • Altos Labs (cellular rejuvenation)

  • Calico (Google aging research)

  • Unity Biotechnology (senolytics)

  • Life Biosciences (multiple approaches)

  • Juvenescence (AI-driven drug discovery)

Consortiums

  • Biomarkers of Aging Consortium

  • Targeting Aging with Metformin (TAME)

  • American Federation for Aging Research (AFAR)

Critical Considerations

Scientific Rigor

  • Most animal research doesn't translate to humans

  • Long-term human studies are limited

  • Individual variation is substantial

  • Beware of overhyped claims

Safety Concerns

  • Cancer risk (telomerase activation, cellular reprogramming)

  • Immune suppression (rapamycin)

  • Unknown long-term effects

  • Drug interactions

Ethical Considerations

  • Access and equity

  • Resource allocation

  • Quality vs. quantity of life

  • Societal impacts of extended lifespan

Regulatory Landscape

  • FDA doesn't recognize aging as disease

  • TAME trial seeking aging indication

  • International regulatory variation

  • Need for standardized biomarkers

References and Further Reading

Foundational Papers

  • López-Otín et al. (2013) "The Hallmarks of Aging" - Cell

  • López-Otín et al. (2023) "Hallmarks of Aging: An Expanding Universe" - Cell

Key Review Articles

Clinical Resources

Related Documents

  • [[Biomarkers of Aging]] - Comprehensive biomarker reference

  • [[Biological Age Assessment]] - Assessment methods and implementation

  • [[Longevity Interventions]] - Evidence-based interventions

  • [[Recent Longevity Research 2025]] - Latest scientific findings

Glossary

Healthspan: Period of life spent in good health, free from chronic diseases and disabilities

Lifespan: Total duration of life from birth to death

Senescence: State of permanent cell cycle arrest with altered function

SASP: Senescence-Associated Secretory Phenotype - inflammatory factors secreted by senescent cells

Autophagy: Cellular self-eating process that degrades and recycles cellular components

Mitophagy: Selective autophagy of mitochondria

Epigenetics: Heritable changes in gene expression without DNA sequence changes

Proteostasis: Maintenance of protein homeostasis through synthesis, folding, and degradation

Inflammaging: Chronic low-grade inflammation associated with aging

Last updated: 2025-12-09 Related tags: #longevity #aging #research #hallmarks #mechanisms #interventions

Previous[WIP] ResearchNext[WIP] Biological Age

Last updated